Literature DB >> 28802937

Apathy in Parkinson's Disease.

Javier Pagonabarraga1, Jaime Kulisevsky2.   

Abstract

The normal maintenance of human motivation depends on the integrity of subcortical structures that link the medial and lateral prefrontal cortex with the limbic system. Apathy is highly prevalent in Parkinson's disease and causes major impact on the quality of life of patients and caregivers, comparable to depression or cognitive impairment. The clinical differentiation of apathy from the emotional symptoms of depression, and from difficulties in planning or organizing mental programs as a consequence of executive dysfunction, may guide a rationale for individualized treatment approach of apathetic symptoms, which is presently lacking. To review the different apathetic syndromes that can be diagnosed in clinical practice by appropriate scales, as well as the brain systems that subserve each syndrome, helps to explain how dopaminergic, antidepressant, or cholinergic medications may lead to individual improvements in apathy.
© 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Apathy; Cognitive impairment; Depression; Dopamine agonists; Methylphenidate; Parkinson's disease

Mesh:

Year:  2017        PMID: 28802937     DOI: 10.1016/bs.irn.2017.05.025

Source DB:  PubMed          Journal:  Int Rev Neurobiol        ISSN: 0074-7742            Impact factor:   3.230


  7 in total

1.  Apathy and impulsiveness in Parkinson disease: Two faces of the same coin?

Authors:  Rosanna Palmeri; Francesco Corallo; Lilla Bonanno; Simona Currò; Paola Merlino; Giuseppe Di Lorenzo; Placido Bramanti; Silvia Marino; Viviana Lo Buono
Journal:  Medicine (Baltimore)       Date:  2022-07-01       Impact factor: 1.817

2.  The relationship between meaning in life and apathy in people with Parkinson's disease: a cross-sectional analysis.

Authors:  Bradley McDaniels; Beatrice Lee; Stuart Rumrill; Kirsteen Edereka-Great; Indu Subramanian
Journal:  Aging Clin Exp Res       Date:  2022-10-21       Impact factor: 4.481

Review 3.  A Stage-Based Approach to Therapy in Parkinson's Disease.

Authors:  Claudia Carrarini; Mirella Russo; Fedele Dono; Martina Di Pietro; Marianna G Rispoli; Vincenzo Di Stefano; Laura Ferri; Filomena Barbone; Michela Vitale; Astrid Thomas; Stefano Luca Sensi; Marco Onofrj; Laura Bonanni
Journal:  Biomolecules       Date:  2019-08-20

4.  The Effects of Safinamide Adjunct Therapy on Depression and Apathy in Patients With Parkinson's Disease: Post-hoc Analysis of a Japanese Phase 2/3 Study.

Authors:  Nobutaka Hattori; Yuki Kogo; Michinori Koebis; Takayuki Ishida; Ippei Suzuki; Yoshio Tsuboi; Masahiro Nomoto
Journal:  Front Neurol       Date:  2022-02-07       Impact factor: 4.003

5.  A Randomized Clinical Trial to Evaluate the Effects of Safinamide on Apathetic Non-demented Patients With Parkinson's Disease.

Authors:  Jaime Kulisevsky; Saul Martínez-Horta; Antonia Campolongo; Berta Pascual-Sedano; Juan Marín-Lahoz; Helena Bejr-Kasem; Ignacio Aracil-Bolaños; Andrea Horta-Barba; Arnau Puig-Davi; Javier Pagonabarraga
Journal:  Front Neurol       Date:  2022-06-02       Impact factor: 4.086

Review 6.  The Promise and Challenges of Developing miRNA-Based Therapeutics for Parkinson's Disease.

Authors:  Simoneide S Titze-de-Almeida; Cristina Soto-Sánchez; Eduardo Fernandez; James B Koprich; Jonathan M Brotchie; Ricardo Titze-de-Almeida
Journal:  Cells       Date:  2020-03-31       Impact factor: 6.600

7.  Apathy-Related Symptoms Appear Early in Parkinson's Disease.

Authors:  Emmie Cohen; Allison A Bay; Liang Ni; Madeleine E Hackney
Journal:  Healthcare (Basel)       Date:  2022-01-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.